Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma Treatment
Medulloblastoma (MB) is the most common malignant central nervous system tumor in pediatric patients. Mainstay of therapy remains surgical resection followed by craniospinal radiation and chemotherapy, although limitations to this therapy are applied in the youngest patients. Clinically, tumors are...
Main Authors: | Sutapa Ray, Nagendra K. Chaturvedi, Kishor K. Bhakat, Angie Rizzino, Sidharth Mahapatra |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-12-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/12/1/61 |
Similar Items
-
The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma
by: David R. Ghasemi, et al.
Published: (2022-01-01) -
Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas
by: Otília Menyhárt, et al.
Published: (2019-03-01) -
Clinicopathological Characteristics of non-WNT/non-SHH Medulloblastoma Cases in a Pediatric Egyptian Cohort
by: Soheir M. Hamam, et al.
Published: (2023-02-01) -
High expression of DNA methyltransferases in primary human medulloblastoma
by: Tímea Pócza, et al.
Published: (2016-06-01) -
Rare cases of medulloblastoma with hypermutation
by: Aditi Bagchi, et al.
Published: (2022-05-01)